Comment on

• Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

  D'Amico G, Garcia-Tsao G, Pagliaro L. D'Amico G, et al. J Hepatol. 2006 Jan;44(1):217-31. doi: 10.1016/j.jhep.2005.10.013. Epub 2005 Nov 9. J Hepatol. 2006. PMID: 16298014 No abstract available.
• EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

  European Association for the Study of the Liver. European Association for the Study of the Liver. J Hepatol. 2010 Sep;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004. Epub 2010 Jun 1. J Hepatol. 2010. PMID: 20633946 Review. No abstract available.
• Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension.

  de Franchis R; Baveno V Faculty. de Franchis R, et al. J Hepatol. 2010 Oct;53(4):762-8. doi: 10.1016/j.jhep.2010.06.004. Epub 2010 Jun 27. J Hepatol. 2010. PMID: 20638742 No abstract available.
• Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.

  Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, Moreau R, Lebrec D. Sersté T, et al. J Hepatol. 2011 Oct;55(4):794-9. doi: 10.1016/j.jhep.2011.01.034. Epub 2011 Feb 24. J Hepatol. 2011. PMID: 21354230 Clinical Trial.